^
    Back
    Association details:
    Biomarker:CD20 expression
    Cancer:Lymphoma
    Drug:NKTR-255 (IL-15R agonist) +
    Ritucad (rituximab biosimilar) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2019
    Title:

    Efficacy and mechanism of action of NKTR-255, a polymer-conjugated IL-15 receptor agonist in hematological tumors.

    Published date:
    05/26/2019
    Excerpt:
    NKTR-255 demonstrated synergistic activity and provided a long-term survival benefit when combined with daratumumab or rituximab in the CD38 and CD20-expressing lymphoma mouse models...
    DOI:
    10.1200/JCO.2019.37.15_suppl.e19512